Deucravacitinib治疗中国内地、台湾和韩国中重度斑块状银屑病的III期随机临床试验
POETYK PSO-3试验纳入220例中国内地、台湾和韩国中重度斑块状银屑病患者,随机1:2接受安慰剂或deucravacitinib 6mg每日一次治疗16周后全部转为deucravacitinib。第16周deucravacitinib组PASI 75和sPGA 0/1应答率显著高于安慰剂组,疗效维持至第52周,安全耐受性良好。
要点
- deucravacitinib 6mg每日一次在中重度斑块状银屑病亚洲患者中第16周PASI 75达68.8%。
- 第16周sPGA 0/1应答率为55.6%,显著优于安慰剂。
- 常见不良事件为上呼吸道感染和鼻咽炎,严重不良事件和停药率低。
核心结论
- deucravacitinib在亚洲中重度斑块状银屑病患者中有效且耐受性良好。
研究设计与样本
- 52周盲法III期POETYK PSO-3试验(NCT04167462),患者随机1:2接受安慰剂(n=74)或deucravacitinib 6mg每日一次(n=146)治疗16周,之后全部接受deucravacitinib。
主要发现
- 第16周deucravacitinib组PASI 75应答率为68.8%,安慰剂组为8.1%(P < 0.001)。
- 第16周deucravacitinib组sPGA 0/1应答率为55.6%,安慰剂组为6.8%(P < 0.001)。
- deucravacitinib的应答率维持至第52周。
- 常见不良事件包括上呼吸道感染和鼻咽炎,严重不良事件和停药率低。
关键数值与推荐
- 共同主要终点为第16周达到PASI 75和sPGA 0/1。
临床怎么用
- deucravacitinib可作为亚洲中重度斑块状银屑病患者的口服治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, is approved in the USA, the European Union, Japan, South Korea, China and other countries for the treatment of moderate-to-severe plaque psoriasis. OBJECTIVES: To evaluate the efficacy and safety of deucravacitinib in Asian patients with moderate-to-severe plaque psoriasis. METHODS: In the 52-week blinded phase III POETYK PSO-3 trial (NCT04167462), patients were randomized 1 : 2 to placebo (n = 74) or deucravacitinib 6 mg once daily (n = 146) for 16 weeks followed by deucravacitinib alone. Co-primary endpoints were the achievement of a ≥75% reduction from baseline in Psoriasis Area and Severity Index (PASI 75) and static Physician Global Assessment score of 0 (clear) or 1 (almost clear; sPGA 0/1) at week 16. Efficacy and safety were evaluated throughout. RESULTS: At week 16, significantly higher proportions of patients receiving deucravacitinib compared with placebo achieved PASI 75 (68.8% vs. 8.1%; P < 0.001) and sPGA 0/1 (55.6% vs. 6.8%; P < 0.001). Response rates with deucravacitinib were maintained through week 52. Common adverse events (AEs) included upper respiratory tract infection and nasopharyngitis. Serious AE and discontinuation rates were low. CONCLUSIONS: Deucravacitinib was efficacious and well tolerated in Asian patients with moderate-to-severe plaque psoriasis. Plaque psoriasis is a skin disease that causes thick and scaly patches called ‘plaques’ on the body. Deucravacitinib (doo-krav-a-sit-in-ib) is a type of medicine for psoriasis. It can stop plaques from forming or improve existing ones. Two clinical trials have shown that deucravacitinib improves psoriasis symptoms within 4 months. We wanted to find out if deucravacitinib works and is safe in Asian people with moderate-to-severe plaque psoriasis. The trial included 220 people from China mainland, Taiwan and South Korea. Some people took deucravacitinib every day for a year. Other people took a placebo (a pill with no active medicine) for the first 4 months and then switched to deucravacitinib. After 4 months, most people who took deucravacitinib saw an improvement in their psoriasis symptoms. They also had skin that was clear or almost clear of psoriasis. People with psoriasis on their scalp also had improved symptoms after taking deucravacitinib. Deucravacitinib continued to work over 1 year. Most people who took part had no serious medical problems during the study. Five patients stopped taking deucravacitinib because of side effects. Five patients developed mild cases of shingles but did not stop taking deucravacitinib. The results suggest that deucravacitinib helps to improve the symptoms of psoriasis in Asian people with psoriasis. The side effects were generally mild.
引用
- Zhang J, Ding Y, Wang P, et al. Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial. Br J Dermatol. 2025. PMID: 39437312. doi:10.1093/bjd/ljae406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。